Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sloning BioTechnology, subsidiary of MorphoSys, and Pfizer have signed a non-exclusive license and technology transfer agreement that covers the installation, training and use of Sloning's technology platform Slonomics for fabrication of gene and protein libraries at Pfizer's subsidiary Rinat Neuroscience in South San Francisco.
Subscribe to our email newsletter
MorphoSys claims that Sloning’s Slonomics technology enables the precise construction of protein libraries comprising defined mixtures of amino acids at pre- determined positions with unprecedented speed.
The MorphoSys subsidiary will receive an upfront payment in 2010, and stands to receive annual license fees over the patent lifetime of the Slonomics technology platform.
MorphoSys CEO Simon Moroney said that this significant alliance around the Slonomics technology, only weeks after they closed the acquisition of Sloning, clearly illustrates the potential value of the platform.
"This alliance with Pfizer creates immediate value for our shareholders and is just the beginning of what we expect to be a considerable return-on- investment from the combined technology platforms of MorphoSys and Sloning in the years ahead," Moroney said.